{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T18:42:11Z","timestamp":1793472131416,"version":"4.5.0"},"reference-count":35,"publisher":"BMJ","issue":"Suppl 1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["James Kiarie"],"award-info":[{"award-number":["James Kiarie"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Sex Reprod Health"],"accepted":{"date-parts":[[2025,9,29]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This narrative review examines the time to return to fertility after discontinuation of subcutaneous depot medroxyprogesterone acetate (DMPA SC) 104\u2009mg among women of reproductive age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The review was conducted using multiple data sources including PubMed, CINAHL, Web of Science, The Cochrane Library, Google Scholar, Ovid Medline, EMBASE, POPLINE, Global Health\/EBSCO, Scopus, WHO Global Index Medicus, International Clinical Trials Registry Platform (ICTRP), Global Index Medicus \u2013 WHO, African Index Medicus (AIM), ScienceDirect, Public Library of Science (PLOS), BioMed Central, Dryad and JSTOR. Search terms included DMPA, SC-DMPA, depot medroxyprogesterone acetate, ovulation, pregnancy, Depo Provera, return to ovulation, fertility, return to fertility, subcutaneous and SubQ. We included studies that used the standard and not experimental dosing of DMPA SC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four of the 31 articles met the inclusion criteria. The trials compared DMPA SC 104\u2009mg with intramuscular DMPA (DMPA IM) at various dosages and routes. Follow-up varied from 7.5 to 18 months after the last injection. Median time to ovulation for DMPA SC was 212 days and was not statistically significantly different from DMPA IM 150\u2009mg (183 days). There were no differences in time to ovulation by region, body mass index or age. No studies reported on time to pregnancy, effect of duration or frequency of dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Median time to ovulation for DMPA SC 104\u2009mg of 212 days was similar to that of DMPA IM 150\u2009mg of 183 days, suggesting that choice of formulation (SC vs IM) does not impact the timeline for return to fertility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjsrh-2025-202839","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T20:05:14Z","timestamp":1762200314000},"page":"s52-s59","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Return to fertility after subcutaneous depot medroxyprogesterone acetate: a narrative review"],"prefix":"10.1136","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-3100","authenticated-orcid":false,"given":"Alfred","family":"Osoti","sequence":"first","affiliation":[{"name":"Obstetrics and Gynaecology, University of Nairobi, Nairobi, Kenya"},{"name":"Global Health, University of Washington School of Public Health, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3447-244X","authenticated-orcid":false,"given":"Nancy","family":"Kidula","sequence":"additional","affiliation":[{"name":"Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3181-6497","authenticated-orcid":false,"given":"Lauryn Busolo","family":"Mengesa","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynaecology, University of Nairobi College of Health Sciences, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4180-7858","authenticated-orcid":false,"given":"James N","family":"Kiarie","sequence":"additional","affiliation":[{"name":"Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"2025110511351257000_51.Suppl_1.s52.1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh058"},{"key":"2025110511351257000_51.Suppl_1.s52.2","unstructured":"World Health Organization (WHO) . Selected Practice Recommendations for Contraceptive Use. 3rd edn. Geneva, Switzerland: WHO, 2016. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK409187\/"},{"key":"2025110511351257000_51.Suppl_1.s52.3","unstructured":"World Health Organization (WHO) . Medical eligibility criteria for contraceptive use. 5th edn. Geneva, Switzerland: WHO, 2015:978\u201392."},{"key":"2025110511351257000_51.Suppl_1.s52.4","unstructured":"World Health Organization Department of Sexual and Reproductive Health and Research (WHO\/SRH) and Johns Hopkins Bloomberg School of Public Health\/ Center for Communication Programs (CCP), Knowledge SUCCESS . Family Planning: A Global Handbook for Providers 2022 Edition. Baltimore and Geneva: CCP and WHO, 2022."},{"key":"2025110511351257000_51.Suppl_1.s52.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.conx.2022.100073","article-title":"Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate","volume":"4","author":"Taylor","year":"2022","journal-title":"Contracept X"},{"key":"2025110511351257000_51.Suppl_1.s52.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2004.01.011"},{"key":"2025110511351257000_51.Suppl_1.s52.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.conx.2021.100070","article-title":"Suppression of ovulation and pharmacokinetics following subcutaneous administration of various doses of Depo-Provera\u00ae: a randomized trial","volume":"3","author":"Halpern","year":"2021","journal-title":"Contracept X"},{"key":"2025110511351257000_51.Suppl_1.s52.8","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.fertnstert.2020.11.002","article-title":"Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera","volume":"115","author":"Halpern","year":"2021","journal-title":"Fertil Steril"},{"key":"2025110511351257000_51.Suppl_1.s52.9","doi-asserted-by":"crossref","first-page":"100080","DOI":"10.1016\/j.conx.2022.100080","article-title":"Return to ovulation after Sayana Press is injected every 4 months for one year: Empirical and pharmacokinetic\/pharmacodynamic modeling results","volume":"4","author":"Taylor","year":"2022","journal-title":"Contraception: X"},{"key":"2025110511351257000_51.Suppl_1.s52.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101273","article-title":"Contraceptive effectiveness, pharmacokinetics, and safety of Sayana\u00ae Press when injected every four months: a multicenter phase 3 trial","volume":"44","author":"Deese","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2025110511351257000_51.Suppl_1.s52.11","doi-asserted-by":"publisher","DOI":"10.1017\/s0021932000014760"},{"key":"2025110511351257000_51.Suppl_1.s52.12","doi-asserted-by":"crossref","unstructured":"Bick AJ , Skosana SB , Avenant C , et al . Variability and quantification of serum medroxyprogesterone acetate levels. Steroids 2022;187. doi:10.1016\/j.steroids.2022.109100","DOI":"10.1016\/j.steroids.2022.109100"},{"key":"2025110511351257000_51.Suppl_1.s52.13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.contraception.2018.03.032","article-title":"Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda","volume":"98","author":"Cover","year":"2018","journal-title":"Contraception"},{"key":"2025110511351257000_51.Suppl_1.s52.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2009.02.005"},{"key":"2025110511351257000_51.Suppl_1.s52.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.03.008"},{"key":"2025110511351257000_51.Suppl_1.s52.16","doi-asserted-by":"crossref","unstructured":"Smith TJ , Urdanigo TK , Shroff N , et al . Patient\u2019s experience and satisfaction with self-administered subcutaneous depot medroxyprogesterone acetate use during the first year of COVID-19. Contraception 2023;123. doi:10.1016\/j.contraception.2023.110008","DOI":"10.1016\/j.contraception.2023.110008"},{"key":"2025110511351257000_51.Suppl_1.s52.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.11.013"},{"key":"2025110511351257000_51.Suppl_1.s52.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2010.01.021"},{"key":"2025110511351257000_51.Suppl_1.s52.19","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2214-109X(18)30061-5","article-title":"Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial","volume":"6","author":"Burke","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2025110511351257000_51.Suppl_1.s52.20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.contraception.2018.02.011","article-title":"Client and provider experiences with self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Malawi","volume":"98","author":"Burke","year":"2018","journal-title":"Contraception"},{"key":"2025110511351257000_51.Suppl_1.s52.21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.contraception.2022.04.007","article-title":"Acceptability of the contraceptive Sayana\u00ae Press when injected every four months: Results from a twelve-month trial in Brazil, Chile and the Dominican Republic","volume":"113","author":"Burke","year":"2022","journal-title":"Contraception"},{"key":"2025110511351257000_51.Suppl_1.s52.22","first-page":"618","article-title":"Body weight and bleeding pattern changes in women using DMPA-SC","volume":"19","author":"Chaudhri","year":"2009","journal-title":"J Coll Physicians Surg Pak"},{"key":"2025110511351257000_51.Suppl_1.s52.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2014.01.026"},{"key":"2025110511351257000_51.Suppl_1.s52.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2004.06.011"},{"key":"2025110511351257000_51.Suppl_1.s52.25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287440","article-title":"Fertility return after hormonal contraceptive discontinuation and associated factors among women attended Family Guidance Association of Ethiopia Dessie model clinic, Northeast Ethiopia: A cross-sectional study","volume":"18","author":"Damtie","year":"2023","journal-title":"PLoS One"},{"key":"2025110511351257000_51.Suppl_1.s52.26","doi-asserted-by":"crossref","unstructured":"Barden-O\u2019Fallon J , Speizer IS , Calhoun LM , et al . Return to pregnancy after contraceptive discontinuation to become pregnant: a pooled analysis of West and East African populations. Reprod Health 2021;18. doi:10.1186\/s12978-021-01193-w","DOI":"10.1186\/s12978-021-01193-w"},{"key":"2025110511351257000_51.Suppl_1.s52.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-3797(01)00316-6"},{"key":"2025110511351257000_51.Suppl_1.s52.28","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6501e1"},{"key":"2025110511351257000_51.Suppl_1.s52.29","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6501e1"},{"key":"2025110511351257000_51.Suppl_1.s52.30","unstructured":"World Health Organization (WHO) . WHO Recommendations: Optimizing health worker roles to improve access to key maternal and newborn health interventions through task shifting. Geneva, Switzerland: WHO, 2012."},{"key":"2025110511351257000_51.Suppl_1.s52.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2017.06.010"},{"key":"2025110511351257000_51.Suppl_1.s52.32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/GCO.0000000000000574","article-title":"Injectable contraception: emerging evidence on subcutaneous self-administration","volume":"31","author":"Lerma","year":"2019","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2025110511351257000_51.Suppl_1.s52.33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/17455057.2.2.191","article-title":"Subcutaneous versus intramuscular depot methoxyprogesterone acetate: a comparative review","volume":"2","author":"Simon","year":"2006","journal-title":"Womens Health (Lond)"},{"key":"2025110511351257000_51.Suppl_1.s52.34","doi-asserted-by":"crossref","DOI":"10.1186\/s40834-018-0064-y","article-title":"Return of fertility after discontinuation of contraception: a systematic review and meta-analysis","volume":"3","author":"Girum","year":"2018","journal-title":"Contracept Reprod Med"},{"key":"2025110511351257000_51.Suppl_1.s52.35","unstructured":"World Health Organization (WHO) . Selected practice recommendations for contraceptive use. 4th edn. Geneva, Switzerland: WHO, 2025."}],"container-title":["BMJ Sexual &amp; Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjsrh-2025-202839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T19:35:20Z","timestamp":1762371320000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1136\/bmjsrh-2025-202839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":35,"journal-issue":{"issue":"Suppl 1","published-online":{"date-parts":[[2025,11,3]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjsrh-2025-202839"],"URL":"https:\/\/doi.org\/10.1136\/bmjsrh-2025-202839","relation":{},"ISSN":["2515-1991","2515-2009"],"issn-type":[{"value":"2515-1991","type":"print"},{"value":"2515-2009","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}